Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.63 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | ADK | P55263 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722191 | 0.83 | NISCH (0.78) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL3885090 | 0.82 | TRPV1 (0.74) | KDM4EALDH1A1TRPV1HDAC6 | |
| SCHEMBL30519171 | 0.81 | HDAC6 (0.45) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL862114 | 0.81 | NISCH (0.75) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL772274 | 0.81 | NISCH (0.58) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL116938 | 0.79 | NISCH (0.55) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL674010 | 0.78 | NISCH (1.00) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL6003473 | 0.77 | CYP1A2 (0.59) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL16382999 | 0.77 | NISCH (0.58) | NISCHMTORADKKDM4EALDH1A1 | |
| SCHEMBL28230038 | 0.76 | NISCH (0.96) | NISCHMTORADKKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116970965-A | Electrochemical incomplete hydrogenation method of imidazopyridine compound | 上海兆维科技发展有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| CN-112805000-A | 2-arylbenzimidazoles as PPARGC1A activators for the treatment of neurodegenerative diseases | 小利兰·斯坦福大学董事会 | 2021-05-14 | — | — | CN | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
| CN-106866661-B | A kind of preparation method of cyanomethylation Imidazopyridine compound | 南京师范大学 | 2019-02-22 | — | — | CN | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| CN-106866661-A | A kind of preparation method of cyanomethylation Imidazopyridine compound | 南京师范大学 | 2017-06-20 | — | — | CN | disclosed |
| CN-106831765-A | 2 (2,6 dicyano phenyl) imidazo [1,2 α] pyridine compounds and theirs and preparation method thereof | 郑州大学 | 2017-06-13 | — | — | CN | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8901142-B2 | Fused tricyclic compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140171456-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-7947684-B2 | anticoagulants; immunomoderators; antiinflammatory agents | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171456-A1 | FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | NISCH 4679/4885MTOR 1/4885ADK 1624/4885 |
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | NISCH 172/4885MTOR 351/4885ADK 3520/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | NISCH 172/4885MTOR 351/4885ADK 3520/4885 |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | NISCH 2526/4885MTOR 163/4885ADK 2476/4885 |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | NISCH 3460/4885MTOR 1/4885ADK 602/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | NISCH 172/4885MTOR 351/4885ADK 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.